Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease

Trends Mol Med. 2020 Nov;26(11):1034-1046. doi: 10.1016/j.molmed.2020.06.006. Epub 2020 Jun 30.

Abstract

Inflammatory bowel disease (IBD) is associated with the production of reactive species that target cysteine redox switches in proteins, thereby affecting gene regulation, DNA damage, ion transport, intermediary metabolism, and mitochondrial function. Precursors of reactive species are derived from organic and inorganic compounds and their cofactors, including amino acids, vitamins, oxygen, nitrite, and sulfate. Nutrition and the gut microbiome fuel this process to a significant extent. The production of reactive species in IBD is reflected by a reduction in systemic free thiols, the major components of the antioxidant machinery. Systemic free thiols are amenable to nutritional or therapeutic intervention. This opens up future avenues for therapeutic modulation of redox status in IBD.

Keywords: free thiols; inflammatory bowel disease (IBD); nutrition; oxidative stress; reactive species interactome (RSI); redox metabolomics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Gene Expression Regulation
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / etiology
  • Inflammatory Bowel Diseases / metabolism*
  • Metabolome
  • Metabolomics / methods
  • Oxidation-Reduction / drug effects*
  • Oxidative Stress / drug effects*
  • Reactive Oxygen Species / metabolism
  • Sulfhydryl Compounds / pharmacology
  • Sulfhydryl Compounds / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Reactive Oxygen Species
  • Sulfhydryl Compounds